Abstract | PURPOSE: MATERIAL AND METHODS: Non-human primates were irradiated at 8.7 Gy whole-body dose with the right arm shielded to receive 4.8 Gy. The first group of animals received G-CSF ( lenograstim) injections starting 6 h after irradiation, and a second group received a combination of G-CSF ( lenograstim) injections and autologous expanded hematopoietic cells. Animals were followed up for blood cell counts, circulating progenitors, and bone marrow cellularity. RESULTS: No significant differences were seen between the two treatment groups, whatever the parameter observed: time to leukocyte or platelet recovery and duration and severity of aplasia. CONCLUSION: Our results indicated that identical recovery kinetic was observed when irradiated animals are treated with G-CSF independently of the reinjection of ex vivo expanded autologous hematopoietic cells. Thus G-CSF injections might be chosen as a first-line therapeutic strategy in the treatment of accidental acute radiation victims.
|
Authors | Jean-Marc Bertho, Johanna Frick, Marie Prat, Christelle Demarquay, Nicolas Dudoignon, François Trompier, Norbert-Claude Gorin, Dominique Thierry, Patrick Gourmelon |
Journal | International journal of radiation oncology, biology, physics
(Int J Radiat Oncol Biol Phys)
Vol. 63
Issue 3
Pg. 911-20
(Nov 01 2005)
ISSN: 0360-3016 [Print] United States |
PMID | 15913916
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Recombinant Proteins
- Granulocyte Colony-Stimulating Factor
- Lenograstim
|
Topics |
- Animals
- Combined Modality Therapy
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Hematopoiesis
(radiation effects)
- Hematopoietic Stem Cell Transplantation
(methods)
- Lenograstim
- Macaca fascicularis
- Male
- Radiation Injuries, Experimental
(therapy)
- Recombinant Proteins
(therapeutic use)
- Syndrome
- Treatment Outcome
|